Artificial intelligence (AI) and machine learning are here to stay, so it’s crucial to understand how they can be used to the best effect in the evolving world of clinical trials.<
Debiopharm Innovation Fund, the Swiss biopharma’s strategic investing arm managing a $150 million fund, is looking to get involved earlier in the investment process with the launch of a new
The latest version of Google DeepMind and Isomorphic Labs’ AlphaFold model can predict the structure and relationships not only of proteins, but “all of life’s molecules”,
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.